Free Trial

ZIVO Bioscience (ZIVO) Competitors

ZIVO Bioscience logo
$13.31 +0.31 (+2.37%)
As of 09/15/2025 03:04 PM Eastern

ZIVO vs. TRDA, SLS, MCRB, HRTX, GNFT, CCCC, SXTC, ENTA, EPRX, and TLSA

Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Entrada Therapeutics (TRDA), SELLAS Life Sciences Group (SLS), Seres Therapeutics (MCRB), Heron Therapeutics (HRTX), GENFIT (GNFT), C4 Therapeutics (CCCC), China SXT Pharmaceuticals (SXTC), Enanta Pharmaceuticals (ENTA), Eupraxia Pharmaceuticals (EPRX), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.

ZIVO Bioscience vs. Its Competitors

ZIVO Bioscience (NASDAQ:ZIVO) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Entrada Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 401.30%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Entrada Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

ZIVO Bioscience has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. ZIVO Bioscience's return on equity of 0.00% beat Entrada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
Entrada Therapeutics -92.30%-17.81%-14.55%

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Entrada Therapeutics has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K3,204.84-$7.78M-$2.58-5.16
Entrada Therapeutics$210.78M0.92$65.63M-$1.78-2.88

In the previous week, Entrada Therapeutics had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Entrada Therapeutics and 2 mentions for ZIVO Bioscience. Entrada Therapeutics' average media sentiment score of 0.98 beat ZIVO Bioscience's score of 0.22 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ZIVO Bioscience
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Entrada Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Entrada Therapeutics beats ZIVO Bioscience on 11 of the 16 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZIVO vs. The Competition

MetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$50.80M$291.50M$5.69B$10.27B
Dividend YieldN/AN/A5.72%4.60%
P/E Ratio-2.73N/A75.8626.51
Price / Sales3,204.84431.33489.92165.32
Price / CashN/A22.4425.8129.89
Price / Book-16.4310.4412.846.32
Net Income-$7.78M-$111.61M$3.28B$270.51M
7 Day Performance-1.42%-2.02%0.20%2.15%
1 Month Performance-27.08%3.60%4.59%6.35%
1 Year Performance2.37%-14.21%68.31%25.48%

ZIVO Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZIVO
ZIVO Bioscience
0.3416 of 5 stars
$13.31
+2.4%
N/A+10.9%$50.80M$15.85K-2.7310Gap Up
TRDA
Entrada Therapeutics
2.5288 of 5 stars
$5.14
-2.7%
$25.67
+399.4%
-66.3%$200.84M$210.78M-2.89110
SLS
SELLAS Life Sciences Group
1.3438 of 5 stars
$1.86
-2.1%
$7.00
+276.3%
+27.3%$200.07M$1M-5.8110
MCRB
Seres Therapeutics
3.2641 of 5 stars
$18.65
-18.4%
$73.67
+295.0%
-21.5%$200.04M$126.32M-4.05330Positive News
High Trading Volume
HRTX
Heron Therapeutics
4.1311 of 5 stars
$1.30
flat
$4.50
+246.2%
-33.7%$199.28M$144.29M-65.00300Positive News
GNFT
GENFIT
1.9033 of 5 stars
$4.04
+1.9%
$9.00
+123.0%
+3.9%$198.01M$76.77M0.00120Upcoming Earnings
CCCC
C4 Therapeutics
2.9659 of 5 stars
$2.68
-1.1%
$8.00
+198.5%
-44.6%$192.87M$35.58M-1.70150News Coverage
Analyst Upgrade
SXTC
China SXT Pharmaceuticals
1.3089 of 5 stars
$1.48
-10.6%
N/A-65.1%$191.45M$1.74M0.0090News Coverage
Positive News
Short Interest ↓
Gap Down
ENTA
Enanta Pharmaceuticals
4.1536 of 5 stars
$9.04
+1.5%
$22.25
+146.1%
-40.0%$190.48M$67.64M-2.09160News Coverage
Analyst Forecast
EPRX
Eupraxia Pharmaceuticals
2.4853 of 5 stars
$5.27
0.0%
$11.00
+108.8%
+105.4%$189.51MN/A-6.2029
TLSA
Tiziana Life Sciences
0.5695 of 5 stars
$1.85
+14.2%
N/A+83.8%$189.29MN/A0.008News Coverage
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:ZIVO) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners